Posaconazole concentrations in the central nervous system

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1468-1470

  Rüping, Maria J G T ^a   Albermann, Nadine ^b   Ebinger, Friedrich ^b   Burckhardt, Irene ^c   Beisel, Claudia ^a   Müller, Carsten ^a   Vehreschild, Jörg J ^a   Kochanek, Matthias ^a   Fätkenheuer, Gerd ^a   Bangard, Christopher ^a   Ullmann, Andrew J ^d   Herr, Wolfgang ^d   Kolbe, Karin ^d   Hallek, Michael ^a   Cornely, Oliver A ^a,e  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antifungal therapy; FungiScope; Invasive fungal infections; Plasma drug levels; Therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B; C REACTIVE PROTEIN; CASPOFUNGIN; OMEPRAZOLE; PANTOPRAZOLE; POSACONAZOLE; PREDNISONE; VORICONAZOLE;

ADOLESCENT; ADULT; ASPERGILLOSIS; BACTERIAL MENINGITIS; BRONCHOPNEUMONIA; CASE REPORT; CENTRAL NERVOUS SYSTEM; DRUG BRAIN LEVEL; DRUG DETERMINATION; FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; LETTER; LIPOSOMAL DELIVERY; LOADING DRUG DOSE; MALE; MAXILLA SINUS TUMOR; MENTAL DETERIORATION; MUCORMYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; FEMALE; HUMANS; MALE; MIDDLE AGED; SERUM; TRIAZOLES;

EID: 56649106673     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn409     Document Type: Letter

References (5)

1. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
2. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
3. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
4. Cornely OA, Maertens J, Winston D et al. Pharmacokinetics (PK) of oral posaconazole (POS) in neutropenic patients with acute myelogenous leukemia (AML). In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract A-1096, p. 21. American Society for Microbiology, Washington, DC, USA.
5. Pitisuttithum P, Negroni R, Graybill JR et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56: 745-55.